全集Pyruvate脱酶激酶抑制剂用于跟踪,准和提高效率
Xiao Zhang1,2, Shrita Sarkar1,2, Akash Ashokan1,2
1Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, University of Miami, Miami, Florida 33136, United States.
Bioconjugate chemistry
|June 6, 2023
概括
这项研究引入了一种新型可追踪的葡萄糖分解抑制剂,旨在在不伤害免疫细胞的情况下向癌细胞. 这一发展为由细胞代谢异常驱动的疾病提供了一个有前途的新疗法策略.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 细胞代谢重编程,特别是增强的葡萄糖分解,是各种疾病的标志,包括癌症.
- 癌细胞中的这种代谢转变会损害线粒体,并可能导致治疗抵抗.
- 癌细胞糖解还会影响瘤微环境中的免疫细胞,促进免疫抑制状态并阻碍抗癌免疫力.
研究的目的:
- 为解决针对性,可追踪性和稳定的葡萄糖分解抑制剂的需要,用于疾病管理.
- 开发一种具有治疗潜力,可追踪性和配方能力的"全合一"糖解抑制剂.
- 在体内乳腺癌模型中评估新型抑制剂的治疗疗效和可追踪性.
主要方法:
- 一种新型葡萄糖分解抑制剂的合成和表征.
- 抑制剂的配方,用于潜在的向输送.
- 在乳腺癌模型中对抑制剂的治疗潜力,可追踪性和糖解抑制的体内评估.
主要成果:
- 成功合成,表征和制备了一种新型可追踪的葡萄糖分解抑制剂.
- 证明抑制剂的向糖解的能力.
- 在体内乳腺癌模型中的治疗潜力的证据,以及其可追踪性.
结论:
- 开发的抑制剂在向依赖糖解的疾病方面取得了重大进展.
- 抑制剂的可追踪性和配方为有针对性的输送和增强的治疗策略提供了潜力.
- 这项工作为新的治疗方法铺平了道路,选择性地准癌细胞代谢,同时保持抗瘤免疫力.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Targets for Drug Action: Overview
6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K


